Ursodiol in Huntington's Disease

• Status: Unknown status
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety of the drug ursodiol (ursodeoxycholic acid, UDCA) in people with Huntington's disease (HD) and to explore how the compound is processed by the body.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborators: Huntington Society of Canada; Huntington Study Group
• Treatments: Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

• All subjects will be age 18 or older

• All subjects will have manifest Huntington disease determined by clinical exam plus either documented prior DNA testing for the HD gene or a documented family history of the disease

Exclusion Criteria:

• Subjects taking oral contraceptives, cholestyramine, colestipol, or aluminum-based antacids will be excluded

• Subjects with known allergy or other contraindication to the study drug will be excluded

• Subjects with bleeding diathesis, or on coumadin or mandatory aspirin will be excluded

• Subjects with unstable medical or psychiatric illness will be excluded

• Subjects with clinically significant lab / EKG abnormalities at screening will be excluded

• Subjects who are currently pregnant or breastfeeding will be excluded